Maryland company makes traditional protein-based vaccination, unlike the dominant mRNA shots, as many Americans remain reluctant to get inoculated

'Alternative' non-mRNA coronavirus shot still subject to regulatory approval; shipment to arrive in coming months, with option to expand by another 5 million shots

Move comes as Omicron variant becoming dominant strain in US and is spurring new waves of infections globally